Journal: Oncotarget

Article Title: DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer

doi: 10.18632/oncotarget.12626

Figure Lengend Snippet: A. Bisulfite sequencing results showed fragment B1 (-764 to -447 bp) of the PAX2 promoter was hypermethylated in endometrial cancer cell lines and tissues: rows represent clones (10 for each sample), columns represent CpG sites. Black squares represent methylated CpGs, and white squares represent unmethylated CpGs. EEC: endometrial epithelial cell. EnCa: endometrial cancer. N: normal. B. MassARRAY results indicate that PAX2 was hypermethylated in endometrial cancer tissues compared with normal endometrial tissues. M1 is an amplicon of a 280-bp fragment from -723 bp to -443 bp; M2 is an amplicon of a 379-bp fragment from -468 bp to -89 bp. Hypermethylated CpG sites were centralized in the 5’ of M1 (CpG 1 to 7).

Article Snippet: The PCR annealing Tm was 56°C, and sample preparation was performed according to “Training Instructions for EpiTYPER Quantitative Methylation Analysis Using MassCLEAVE for MassARRAY” (Sequenom).

Techniques: Methylation Sequencing, Clone Assay, Methylation, Amplification

Journal: Cancers

Article Title: BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

doi: 10.3390/cancers12040828

Figure Lengend Snippet: Correlation between methylation-specific PCR and EpiTYPER® MassARRAY® methylation evaluation ( n = 153). Black columns indicate discordant cases ( n = 4, methylation percentage assessed by MassARRAY® = 9.5, 6, 4, and 4), using a positivity cut-off of 10%.

Article Snippet: The key secondary endpoint was the evaluation of the concordance between the determination of BRCA1 promoter methylation status by the quantitative EpiTyper ® MassARRAY ® (Agena Bioscience, Sans Diego, CA, USA) and by MS-PCR.

Techniques: Methylation

Journal: Cancers

Article Title: BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

doi: 10.3390/cancers12040828

Figure Lengend Snippet: Univariate clinicopathological correlations with BRCA1 promoter methylation using MS-PCR.

Article Snippet: The key secondary endpoint was the evaluation of the concordance between the determination of BRCA1 promoter methylation status by the quantitative EpiTyper ® MassARRAY ® (Agena Bioscience, Sans Diego, CA, USA) and by MS-PCR.

Techniques: Methylation, Expressing

Journal: Cancers

Article Title: BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

doi: 10.3390/cancers12040828

Figure Lengend Snippet: Distribution of CpG sites analyzed in the promoter region of the BRCA1 gene. ( A ) The BRCA1–NBR2 locus: the position of the first exons of the BRCA1 is indicated by shaded boxes. The first exon of NBR2 gene is indicated by a black box. ( B ) Position of CpG sites analyzed Cytosine on CpG sites tested by MS-PCR are underlined. Cytosine on CpG sites tested by MassARRAY® EpiTYPER® assay are in bold. The positive strand of the BRCA1 gene is shown based on GenBank accession number U37574. The transcription start site of the BRCA1 exon 1A is marked by an arrow. Exon 1A sequence is in capital, and both 5’upstream sequence and intron 1 sequence are in lower case characters.

Article Snippet: The key secondary endpoint was the evaluation of the concordance between the determination of BRCA1 promoter methylation status by the quantitative EpiTyper ® MassARRAY ® (Agena Bioscience, Sans Diego, CA, USA) and by MS-PCR.

Techniques: MassARRAY EpiTYPER assay, Sequencing